secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001104659-24-055838
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio CFO Henry Hagopian resigns; CEO Maria Maccecchini named interim CFO
-------------------------------------------------------------------------------

- Henry Hagopian stepped down as CFO effective April 30, 2024, to pursue other opportunities; no disagreement with company.
- CEO Maria Maccecchini appointed as interim principal financial officer effective May 1, 2024.
- Severance includes 2 months base salary ($62,500) plus $3,000 medical/dental reimbursement, paid as lump sum.
- Company accelerates vesting of 10,000 stock options and extends exercise period for certain options through Dec 31, 2024.
- Hagopian signed a separation agreement with a general release of claims and non-disparagement obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924055838/0001104659-24-055838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924055838/tm2413238d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-055838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer